Multiple studies highlight progress in immunotherapy and neurological diseases. Engineered IL-18 variants with improved pharmacological properties show promise for cancer treatments. Myogenic progenitor cell therapy derived from induced pluripotent stem cells exhibits preclinical potential for muscular dystrophies. Additionally, research reveals mechanisms of immune evasion in colorectal cancer linked to NK cell dysfunction, and dual activation of GLP-1 and GIP receptors confers neuroprotection in Parkinson’s models.